January 2007
Worldwide Biotech;Jan2007, Vol. 19 Issue 1, p1
Trade Publication
The article reports that SemBioSys Genetics Inc. has signed a Technology Transfer and Manufacturing Agreement with Cangene Corp. Insulin will be manufactured by Cangene for the preclinical and early stage clinical development of SemBioSys. The remarks of SemBioSys president Andrew Baum on the contract's execution are presented.


Related Articles

  • Canadian biotech firm signs agreement for plant-produced insulin.  // Pharmaceutical Technology Europe;Jan2007, Vol. 19 Issue 1, p14 

    The article reports on the completion of SemBioSys Genetics Inc. of a technology transfer and manufacturing agreement with Cangene Corp. for the processing and purification of SemBioSys' plant-produced insulin in Gerat Britain. The contract is part of its investigational new drug (IND) and...

  • DIGEST.  // Chemical Week;4/11/2007, Vol. 169 Issue 13, p31 

    The article presents news briefs on the chemical industry. Nippon Kayaku says it plans to increase manufacturing capacity for high-potency active pharmaceutical ingredients. Cambrex says it has approved a one-time payment of $14 per share to shareholders through a special cash dividend....

  • Insulin grown in safflowers tested in people.  // New Scientist;1/10/2009, Vol. 201 Issue 2690, p4 

    The article focuses on a trial conducted by Sembiosys Genetics to test a type of insulin grown in safflowers. The company inserted human insulin genes into safflowers, causing them to make a compound called pro-insulin, which was then converted into a type of insulin called SBS-100. Previous...

  • Cangene Corporation.  // Pharmaceutical Technology;Dec2008 Supplement, p93 

    The article profiles Cangene Corp. in Winnipeg, Manitoba. The biopharmaceutical company has developed a successful track record in contract manufacturing by applying its technical expertise and first-class facilities to add value to customer's projects. Its services include current Good...

  • industrial.  // R&D Magazine;Aug2006, Vol. 48 Issue 8, p31 

    The article presents updates on scientific research and developments in the industrial sector as of August 2006. SemBioSys Genetics Inc. has produced an authentic insulin molecule in safflower with 1.2% of total seed protein. A miniature wireless data chip, developed by Hewlett-Packard, could...

  • MannKind Licenses SemBioSys' Plant-Produced Insulin.  // BioPharm International;Feb2009, Vol. 22 Issue 2, p13 

    The article reports on Mannkind Corp.'s purchase of an option to license plant-produced recombinant human insulin from SemBioSys Genetics Inc. in Canada for use in the earlier's ultra-rapid acting insulin, Afresa. The said plant-produced insulin from SemBioSys is human insulin from genetically...

  • SemBioSys, Roslin Institute Make Proteins from GM Organisms. Scott, Alex // Chemical Week;1/24/2007, Vol. 169 Issue 3, p35 

    The article reports on the production of insulin using genetically modified (GM) safflower plants. Biotechnology firm SemBioSys Genetics has produced insulin that is indistinguishable from human insulin. SemBioSys plans to submit an Investigational New Drug Application to the U.S. Food and Drug...

  • SEMBIOSYS GETS ALBERTA AWARD FOR PLANT BIOTECHNOLOGY.  // Worldwide Biotech;Dec2002, Vol. 14 Issue 12, p6 

    Reports on the Alberta Science and Technology Award for Innovation in Industrial Research Prize received by biotechnology company SemBioSys Genetics Inc. for its contributions to plant biotechnology.

  • Financings Roundup.  // BioWorld Today;2/22/2011, Vol. 22 Issue 35, p3 

    The article reports on the modification made by SemBioSys Genetics Inc. on its proposed 4 million dollar financing.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics